Apollomics Inc Dossier - Source-backed chat

Apollomics Inc

APLMNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.28

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $24.95Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $72.7M

Enterprise Value $63M

Shares Outstanding 2.9M diluted

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Apollomics Inc. is a clinical-stage biopharmaceutical company undergoing a critical strategic turnaround. While the company successfully reduced its operating expenses by 64% in 2025 and recorded $8.5 million in revenue from an upfront licensing agreement, it faces severe going-concern risks with only $3.3 million in cash as of December 31, 2025. The pipeline is highly concentrated on its lead candidate, vebreltinib (APL-101), following the full impairment of uproleselan. Given the high clinical development risks, indefinite deferral of the U.S. NDA for METex14 skipping NSCLC, and tight liquidity, a Hold recommendation is warranted until further financing is secured and clinical milestones are met.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.5020%

The company fails to secure additional capital before its cash runway expires in Q3 2026, leading to severe liquidity distress, potential winding-up, or delisting from Nasdaq. Clinical trials face further enrollment delays or unfavorable safety/efficacy readouts.

Base CaseCentral scenario

$14.0060%

The company successfully submits its Phase 2/3 IND for vebreltinib in combination with an EGFR inhibitor in the U.S. and select Asian countries by H1 2027. It secures additional bridge financing or equity funding to extend its cash runway past Q3 2026, avoiding delisting or insolvency.

Scenarios reflect our research view at the research date.

Key Investment Merits

Vebreltinib is already approved in China for three distinct indications, validating its biological mechanism.
Significant cost-reduction initiatives successfully reduced annual operating expenses by 64% in 2025.
Strong insider support, demonstrated by a $2.0 million convertible bridge loan from the CEO in March 2026.

Key Investment Risks

Severe going-concern risk with cash reserves only projected to fund operations into Q3 2026.
High pipeline concentration risk following the $10.0 million full impairment of uproleselan.
Potential Nasdaq delisting risks and historical high stock price volatility.

Thesis Invalidation Triggers

Failure to submit the U.S. IND for vebreltinib by the end of 2027.
Inability to secure additional funding by Q3 2026, resulting in insolvency proceedings.
Delisting of Class A ordinary shares from the Nasdaq Stock Market.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.